Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals reported consolidated revenue of Rs 1,69,825 million for FY2026, up 27.5% from Rs 1,33,217 million in FY2025, driven by strong performance in its pharmaceutical generics and API businesses. Consolidated PAT grew 30% to Rs 13,619 million from Rs 10,471 million. However, the company faced significant exceptional charges of Rs 22,661 million, primarily from antitrust litigation settlements (Rs 6,989 million), inventory provisions for GST 2.0 changes (Rs 5,901 million), receivables provisions (Rs 4,958 million), and PPE impairment (Rs 2,279 million). At standalone level, the company reported a net loss of Rs 2,008 million versus profit of Rs 16,104 million in FY2025 due to these exceptional items. The Board recommended a dividend of Rs 2.5 per share (250%). Auditors issued an unqualified opinion.
Strong revenue and PAT growth demonstrates operational strength, but large exceptional charges from litigation and inventory changes suppressed bottom line. The stock may see mixed reaction as underlying business looks healthy despite headline loss at standalone level.